MA40937A - Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation - Google Patents

Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation

Info

Publication number
MA40937A
MA40937A MA040937A MA40937A MA40937A MA 40937 A MA40937 A MA 40937A MA 040937 A MA040937 A MA 040937A MA 40937 A MA40937 A MA 40937A MA 40937 A MA40937 A MA 40937A
Authority
MA
Morocco
Prior art keywords
oxymorphone
benzoic acid
conjugates
manufacturing
heteroarylcarboxylic
Prior art date
Application number
MA040937A
Other languages
English (en)
Inventor
Sanjib Bera
Sven Guenther
Jaroslaw Kanski
Andrea Martin
Travis Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of MA40937A publication Critical patent/MA40937A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente technologie offre des compositions comprenant des acides arylcarboxyliques et, par exemple, des anti-inflammatoires non stéroïdiens (ains), des conjugués chimiquement à l'oxymorphone (4,5-α-époxy-3,14-hydroxy-17-méthylmorphinan-6-one) pour obtenir de nouveaux promédicaments/compositions d'oxymorphone, y compris des benzoates, salicylates, propionates, fénamates et acétates, qui ont un potentiel réduit en termes d'abus d'oxymorphone. La présente technologie concerne également des procédés de traitement de patients, des kits pharmaceutiques et des procédés de synthèse de conjugués selon la présente invention.
MA040937A 2014-12-02 2015-12-02 Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation MA40937A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462086326P 2014-12-02 2014-12-02

Publications (1)

Publication Number Publication Date
MA40937A true MA40937A (fr) 2017-10-11

Family

ID=55022688

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040937A MA40937A (fr) 2014-12-02 2015-12-02 Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation

Country Status (19)

Country Link
US (4) US9682076B2 (fr)
EP (1) EP3226907A1 (fr)
JP (2) JP6462877B2 (fr)
KR (1) KR20170094251A (fr)
CN (1) CN106999487A (fr)
AU (1) AU2015358606B9 (fr)
BR (1) BR112017011764A2 (fr)
CA (1) CA2969221C (fr)
CL (1) CL2017001417A1 (fr)
CO (1) CO2017005203A2 (fr)
HK (1) HK1244209A1 (fr)
IL (1) IL252472A0 (fr)
MA (1) MA40937A (fr)
MX (1) MX2017006935A (fr)
NZ (1) NZ731586A (fr)
PH (1) PH12017500859A1 (fr)
RU (1) RU2683274C2 (fr)
SG (1) SG11201704309YA (fr)
WO (1) WO2016089951A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731586A (en) 2014-12-02 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
RU2657803C1 (ru) * 2017-03-21 2018-06-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" Средство, обладающее противовоспалительным и анальгезирующим действием
US11254685B2 (en) * 2017-07-20 2022-02-22 Suzhou Runxindatai Pharmaceutics Ltd Co. Abuse-resistant long-acting release opioid prodrugs
CN111836813A (zh) 2018-02-23 2020-10-27 罗德科技公司 新型阿片样化合物及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
RU2166512C2 (ru) 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Конъюгаты терапевтического соединения с жирной кислотой
DE19602964A1 (de) 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
JP4806507B2 (ja) 1999-10-29 2011-11-02 ユーロ−セルティーク エス．エイ． 制御放出ヒドロコドン処方
WO2005032474A2 (fr) 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Compositions pharmaceutiques pour prevenir une dose excessive ou un abus
DE60239801D1 (de) 2001-06-05 2011-06-01 Control Delivery Systems Watertown Analgetika mit verzögerter wirkstoffabgabe
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
DE602004024963D1 (de) 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
JP2009533459A (ja) 2006-04-14 2009-09-17 シャイア エルエルシー 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法
WO2007140272A2 (fr) * 2006-05-26 2007-12-06 Pharmacofore, Inc. Libération régulée d'opioïdes phénoliques
CA2668074A1 (fr) 2006-10-31 2008-05-08 David Schwaab Systeme de masquage automatique de structures de repertoire de donnees et de fichiers enregistrees sur une memoire d'ordinateur
US20120142718A1 (en) 2007-02-16 2012-06-07 Jenkins Thomas E N-17-Alkylated Prodrugs of Opioids
WO2009092071A2 (fr) 2008-01-18 2009-07-23 Shire Llc Promédicaments à base d'acides aminés et de peptides d'analgésiques phénoliques et leurs utilisations
AU2010231126A1 (en) 2009-04-02 2011-10-13 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US20120142720A1 (en) 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
WO2011008636A1 (fr) 2009-07-15 2011-01-20 Mallinckrodt Inc. Dérivés de 3-oxy-hydromorphone
US20120115778A1 (en) 2009-07-15 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2
US20110015219A1 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
BR112012005124B1 (pt) 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
PL2593095T3 (pl) * 2010-07-16 2019-12-31 Mallinckrodt Llc (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
WO2012122420A2 (fr) 2011-03-09 2012-09-13 Pharmacofore, Inc. Promédicaments opioïdes présentant des groupes de liaison hétérocycliques
SG11201401856VA (en) 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
NZ731586A (en) 2014-12-02 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof

Also Published As

Publication number Publication date
JP6462877B2 (ja) 2019-01-30
HK1244209A1 (zh) 2018-08-03
US20160151352A1 (en) 2016-06-02
PH12017500859A1 (en) 2017-11-06
CO2017005203A2 (es) 2017-08-31
US20180338968A1 (en) 2018-11-29
WO2016089951A1 (fr) 2016-06-09
US10071091B2 (en) 2018-09-11
IL252472A0 (en) 2017-07-31
RU2017123161A3 (fr) 2019-01-09
CA2969221C (fr) 2021-01-12
US20200030316A1 (en) 2020-01-30
JP2019077695A (ja) 2019-05-23
CA2969221A1 (fr) 2016-06-09
SG11201704309YA (en) 2017-06-29
AU2015358606B9 (en) 2019-05-02
NZ731586A (en) 2018-06-29
CN106999487A (zh) 2017-08-01
MX2017006935A (es) 2017-08-10
US20170312270A1 (en) 2017-11-02
EP3226907A1 (fr) 2017-10-11
BR112017011764A2 (pt) 2018-07-10
AU2015358606A1 (en) 2017-05-25
US10463660B2 (en) 2019-11-05
RU2683274C2 (ru) 2019-03-27
KR20170094251A (ko) 2017-08-17
US10758528B2 (en) 2020-09-01
AU2015358606B2 (en) 2019-04-18
JP2017538696A (ja) 2017-12-28
US9682076B2 (en) 2017-06-20
CL2017001417A1 (es) 2018-02-09
RU2017123161A (ru) 2019-01-09

Similar Documents

Publication Publication Date Title
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EP2868667A4 (fr) Agent thérapeutique à base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anémie, notamment une anémie rénale et une anémie liée à un cancer
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
EP2823819A4 (fr) Composition pharmaceutique contenant de l'acétate d'acide oléanolïque en tant que principe actif pour la prévention ou le traitement de maladie à médiation par tlr ou il-6
ECSP099239A (es) Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas
MA38399B2 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
CY1122626T1 (el) Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA40937A (fr) Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
JP2016513650A5 (fr)
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
MA50458A (fr) Formulations topiques destinées au traitement d'affections dermatologiques comprenant la calvitie hippocratique
BRPI0506615A (pt) composição de moléculas de estrutura lipofìlica, comprimido e utilização de uma composição
MA53521A1 (fr) Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
EP3524239A4 (fr) Composition comprenant de l'acétate d'acide oléanolique en tant que principe actif pour prévenir, atténuer ou traiter une toxicité rénale induite par un médicament
MA38521B1 (fr) Formulation d'acétate d'abiratérone utilisé dans le traitement du cancer de la prostate resistant a la castration